The use of panitumumab in the treatment of chemoresistant metastatic sigmoid colon adenocarcinoma: a clinical case

Background. Colon cancer is one of the most common malignancies worldwide. At the same time, about 30% of patients at the time of diagnosis have a disseminated tumor process. Despite the progress in pharmacotherapy of patients with metastatic colorectal cancer over the past 15 years, 5-year survival is still relatively low. Panitumumab, a fully human monoclonal antibody that blocks the epidermal growth factor receptor (EGFR), significantly increases the life expectancy of patients with this pathology. The drug is approved for the treatment of RAS wild-type advanced colorectal cancer in combination with chemotherapy as the first- or second-line of therapy or as monotherapy for chemoresistant cancer. Description of the clinical case. We present a clinical case of the treatment of a 71-year-old patient with disseminated sigmoid colon adenocarcinoma and progression after three lines of therapy. The patient underwent 12 cycles of chemotherapy according to the FOLFOX-6 regimen in combination with panitumumab. The maximum treatment effect was partial regression. Conclusion. Our clinical experience demonstrates that therapy with panitumumab in combination with FOLFOX-6 chemotherapy allows to achieve an objective effect, increase the time to progression and overall survival in previously treated patients with metastatic colon cancer.

metastatic colorectal cancer, targeted therapy, EGFR inhibitors, panitumumab